Lowenstein represented H.C. Wainwright & Co. as exclusive lead placement agent in a public offering for Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM), the aggregate gross proceeds of which are expected to be approximately $25 million. The offering closed on June 19, 2020.
Actinium is a clinical-stage biopharmaceutical company developing Antibody Radiation-Conjugates (ARCs) for targeted conditioning, intended to selectively kill patient's cancer cells and certain immune cells prior to a bone marrow transplant or other cell or gene therapies.
Actinium intends to use the net proceeds from the offering to complete its ongoing pivotal, Phase 3 SIERRA trial for its lead product candidate, Iomab-B.
The Lowenstein deal team included Steven M. Skolnick, Michael J. Lerner, Robert J. Paradiso, James C. Shehan, Tracy F. Buffer, Alexander Dinur, and Madeline Roe.
About Lowenstein Sandler LLP
Lowenstein Sandler is a national law firm with over 350 lawyers based in New York, Palo Alto, New Jersey, Utah, and Washington, D.C. The firm represents leaders in virtually every sector of the global economy, with particular emphasis on investment funds, life sciences, and technology. Recognized for its entrepreneurial spirit and high standard of client service, the firm is committed to the interests of its clients, colleagues, and communities.
Stephen J. Kimmerling
Director, Marketing Communications
Lowenstein Sandler LLP
T: +1 973.597.6176